Session: 45. PK/PD Studies Thursday, October 9, 2014: 12:30 PM Background. In recent guidelines, trough serum concentraions of ≥ 15 µg/mL are recommended for vancomycin in severe infections by less-susceptible staphylococcal species such as MRSA. However, optimal doses to attain the trough value in febrile neutropenic (FN) patients are not yet well established.
Methods. To evaluate the influence of neutropenia on the pharmacokinetics and dosage requirements of vancomycin, the trough levels in 8 patients (Goup C; age 59.0 ± 9.1) without neutropenia (≥ 1,000/μL) were compared with those in 7 patients (Group B; age 61.3 ± 12.6) with mild (100 -1,000/ μL) or in 8 patients (Group A; age 58.5 ± 9.2) with severe (<100/μL) febrile neutropenia using a two-compartment Bayesian pharmacokinetic program. All patients received 2g/day of vancomycin for more than 2 days. Only patients with estimate creatinine clearance (eCCr) more than 70 mL/ minute were included in the study.
Results. Increased total clearance and the shorter elimination-half life of vancomycin was observed in patients with neutropenia compared with non-neutropenic patients, and thus, serum vancomycin concentration (SVC) was significantly lower in neutropenic patients [Group A 9.6 ± 1.7, Group B 10.8 ± 2.6, Group C 14.7 ± 1.3, p < 0.01]. Severely neutropenic patients in particular required a higher vancomycin dosage regimen compared with the non-neutropenic patients [Group A 62.2 ±12.5 mg/kg/day vs Group C 40.0 ± 8.1 mg/kg/day, p = 0.007] to attain trough SVC of 15 mg/mL. Significant inverse association was observed between SVC and eCCr in neutropenic, but not in non-neutropenic patients [Group A ( p = 0.006), Group B ( p = 0.041), Group C patients ( p = 0.610)].
Conclusion. Higher initial doses considering the degree of neutropenia and eCCr, and careful monitoring of the serum concentraions thereafter are required for vancomycin in patients with febrile neutropenia.
Disclosures. 
